News

Xeljanz (tofacitinib) showed promising results for ankylosing spondylitis (AS) patients in a 16-week Phase 2 clinical trial. AS patients with active disease receiving Xeljanz treatment showed great improvement in symptoms and clinical disease profiles when compared to patients treated with placebo. The study, “Tofacitinib in patients with ankylosing…

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Cyltezo, a Humira (adalimumab) biosimilar, for the treatment of multiple chronic inflammatory diseases, including severe active ankylosing spondylitis (AS). The maker of Cyltezo, Boehringer Ingelheim, submitted a marketing…

After analyzing 80 axial spondyloarthritis (axSpA) patients, a French research team found a lower bone mineral density (BMD, or weaker bones) among those who also have a lower body mass index (BMI). The results were reported in a study titled “Prevalence and risk factors of low bone mineral density…

Obese patients with axial spondyloarthritis are less likely to respond to treatment with TNF blockers than patients at a healthy weight, according to a study suggesting that weight loss could improve treatment outcomes. Heavier patients who received Remicade (infliximab) — whose doses are based on weight — did not have…

Patients with chronic inflammatory disorders, including ankylosing spondylitis, are at a higher risk of experiencing multiple cardiometabolic events than matching controls with no inflammatory disease. The risk was almost three times higher for those treated with non-steroidal anti-inflammatory drugs (NSAIDs) compared with those without an inflammatory disease, leading researchers to urge…

The European Commission recently granted a marketing authorization for Imraldi, a biosimilar approved to treat the same inflammatory diseases — including ankylosing spondylitis — as  Humira (adalimumab). Imraldi, developed by Samsung Bioepis — a partnership between Samsung BioLogics and Biogen — is…

Health Canada has approved Sandoz’s Erelzi, a biosimilar therapy of etanercept, for the treatment of ankylosing spondylitis and two other conditions targeted by Amgen’s original therapy Enbrel. Canadian health authorities said that Erelzi has shown to be equally effective in treating ankylosing spondylitis,…

A large-scale survey is underway for patients with a definite diagnosis of ankylosing spondylitis and who know their blood type. The survey will allow researchers to determine whether blood type may be linked to a higher risk of developing autoimmune diseases. Early this year, the Scleroderma Education project conducted a…

African-Americans are more likely to develop severe ankylosing spondylitis (AS), with greater loss of function and higher disease activity, than either white Americans or Latinos, a new study revealed. The study, “Ethnicity and disease severity in ankylosing spondylitis a cross-sectional analysis of three ethnic groups,” was led by researchers at…

Renflexis (infliximab-abda), a biosimilar of Remicade (infliximab), is now available in the United States for the treatment of ankylosing spondylitis and other conditions. The launch was recently announced by Samsung Bioepis as the company’s first biosimilar approved in the U.S. Renflexis was approved by the U.S. Food and Drug Administration (FDA) in…